Iloperidone Novartis

IDrugs

Volumn 5, Issue 1, 2002, Pages 84-90

  Hesselink, J M Keppel ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; HALOPERIDOL; ILOPERIDONE; P 88 8991; P 95 12113; PLACEBO; RISPERIDONE; SEROTONIN 2 RECEPTOR; SPIPERONE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BALANCE DISORDER; BRAIN METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPERPROLACTINEMIA; LABORATORY TEST; LEUKOPENIA; LIGAND BINDING; NAUSEA; NEUTROPENIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHYSICAL EXAMINATION; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; SYNCOPE; TACHYCARDIA; VERTIGO;

EID: 0141784133     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. 50 values for the effects of iloperidone in a variety of preclinical tests in rats and mice.
2. 176933 Effects of atypical antipsychotic agents on social behavior in rodents. Corbett R, Hartman H, Kerman LL, Woods AT, Strupczewski JT, Helsley GC, Conway PC, Dunn RW Pharmacol Biochem Behav 1993 45 1 9-17
3. 191089 The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. Szewczak MR, Corbett R, Rush DK, Wilmot CA, Conway PG, Strupczewski JT, Cornfeldt M J Pharmacol Exp Ther 1995 274 3 1404-1413 Report on ligand binding data and general pharmacological profile on iloperidone. Report on the effect of iloperidone in behavioral tests in monkeys.
4. 193172 Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone. Mutlib AE, Strupczewski JT, Chesson SM Drug Metab Dispos 1995 23 9 951-964
5. 197470 Iloperidone (HP 873). Clin Trials Monitor 1996 5 1 P52 16524 Report on safety and tolerability of iloperidone in human healthy volunteers.
6. 198142 Serotonin receptors in the central nervous system: Targets for new therapeutic agents, IBC Philadelphia, USA. IDDB Meeting Report 1996 January 25-26 Report on pharmacological profile of iloperidone indicating that phase II studies are ongoing.
7. 216445 HMR refines development strategy. Scrip 1996 2129 15
8. 223715 Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP873), a potential atypical antipsychotic. Sainati SM, Hubbard JW, Chi E, Grasing K, Brecher MB J Clin Pharmacol 1995 35 7 713-720 Report on safety and tolerability of iloperidone in human healthy volunteers.
9. 229500 Titan Pharmaceuticals licenses iloperidone from Hoechst Marion Roussel. Titan Pharmaceuticals Inc Press Release 1997 January 09
10. 270037 Titan Pharmaceuticals signs global agreement with Novartis for development and marketing of the antipsychotic product iloperidone. Titan Pharmaceuticals Inc Press Release 1997 November 20
11. 278476 Iloperidone: Preclinical profile and early clinical evaluation. Corbett R, Griffiths L, Shipley JE, Shukla U, Strupczewski JT, Szczepanik AM, Szewczak MR, Turk DJ, Vargas HM, Kongsamut S, Allen RC et al. CNS Drug Rev 1997 3 2 120-147
12. 282654 Iloperidone binding to human and rat dopamine and 5-HT receptors. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A Eur J Pharmacol 1996 317 2-3 417-423
13. 295127 Phase III program starts for novel antipsychotic agent iloperidone. Titan Pharmaceuticals Inc Press Release 1998 August 18
14. 307294 Safety and steady-state pharmacokinetics of a new oral antipsychotic agent, iloperidone, administered to schizophrenic patients. Sha X, Shukla U, Dix R, Shipley JE, Chi E Pharm Res 1996 13 9 Suppl S115
15. 312711 The mechanism of action of novel antipsychotic drugs. Meltzer HY Schizophr Bull 1991 2 263-287
16. 312714 HP 873, a potential atypical antipsychotic agent: Pharmacokinetics in rats and dogs. Chesson SM, Hsu RS, Dileo EM, Strupczewski JT Pharmacologist 1991 33 177-182
17. 312715 Efficacy of 5 mg/day and 8 mg iloperidone administered to schizophrenic patients for 42 days. Borison RL, Huff FJ, Griffiths L Psychopharmacol Bull 1996 32 416
18. 312824 A summary of new research findings on the new antipsychotic drugs. Gibson MD, Tandon R Essential Psychopharmacol 1996 1 27-37
19. 342937 Novartis R&D Investor Seminar, New York. Novartis AG Company World Wide Web Site 1999 September 21
20. 364082 Novartis - Operational Review 1999. Novartis AG Annual Report 2000 January 01
21. 374972 Receptor affinity of two human metabolites of iloperidone, a new antipsychotic agent. Subramanian N, Kalkman HO Int J Neuropsychopharmacol 2000 3 Suppl 1 P.01.163
22. 2c-adrenoceptors. Loetscher E Int J Neuropsychopharmacol 2000 3 Suppl 1 P.01.164
23. 383412 Titan announces positive results for Zomaril phase III clinical trial in schizophrenia. Titan Pharmaceuticals Inc Press Release 2000 September 25
24. 389740 Titan Pharmaceuticals Inc announces third quarter 2000 financial results. Titan Pharmaceuticals Inc Press Release 2000 November 14
25. 400976 Financial results 2000 presentation (Basel/New York). Novartis AG Company World Wide Web Site 2001 February 15-16
26. 402747 Titan reports fourth quarter and year end results. Titan Pharmaceuticals Inc Press Release 2001 March 22
27. 407075 Titan Pharmaceuticals Inc signs agreement with Novartis Pharma AG for development and commercialization of Zomaril in Japan. Titan Pharmaceuticals Inc Press Release 2001 April 25
28. 416616 Titan and Novartis plan additional clinical trials to further strengthen profile of iloperidone for the treatment of schizophrenia. Titan Pharmaceuticals Inc Press Release 2001 July 23
29. 426327 Suspension of Serdolect lifted. H Lunbeck AS Press Release 2001 October 19
30. 427583 The management of cultural differences and the importance of safety monitoring in global studies: The ReALIZE clinical program. Kalali A, Lasser R, Campbell B et al World Congr Biol Psychiatry 2001 7th Berlin
31. 427586 Effect of iloperidone on cerebral metabolism in patients. Potkin S, Young F, Alva G et al World Congr Biol Psychiatry 2001 7th Berlin
32. 427590 A prospective, double-blind, randomized, parallel-group, placebo-controlled study of iloperidone in treatment of psychotic and behavioral symptoms in elderly patients with dementia. Lasser RA, Campbell B, Hourani J, Gharabawi M World Congr Biol Psychiatry 2001 7th Berlin
33. 427596 A randomized, double blind, multicenter phase III study of iloperidone versus haloperidol and placebo in patients with schizophrenia or schizoaffective disorder. Cucchiaro J, Nann Verontica E, Matovits Gupta T et al World Congr Biol Psychiatry 2001 7th Berlin
34. 427598 Safety and efficacy of iloperidone in patients with psychotic disorders: A randomized double-blind multicenter study. Matkovitis Gupta T, Cucchiaro J, Ell Bizri H et al World Congr Biol Psychiatry 2001 7th Berlin
35. 427613 The broad spectrum profile of Zomaril tailored for the treatment of psychotic disorders. Kalkman HO World Congr Biol Psychiatry 2001 7th Berlin
36. 427620 Managing psychotic disorders through balanced receptor blockade: The iloperidone clinical plan. Matkovits Gupta T, Cucchiaro J, Fairwheather D, et al World Congr Biol Psychiatry 2001 7th 1-6 July, Berlin
37. 429516 Titan reports third quarter 2001 results. Titan Pharmaceuticals Inc Press Release 2001 November 15
38. 429750 Healthcare - Major Pharmaceuticals. Company Update - Novartis: R&D Day Preview. Adkins S, Heath K, Hetzel C, Smith IR, Walton J Lehmann Brothers 2001 October 25
39. 431614 2nd Annual CSFB European Large Cap Pharmaceutical Conference, London. Novartis AG Company Presentation 2001 November 21